**7. References**


Predictors of the Common Adverse Drug Reactions of Statins 467

[22] Silva MA, Swanson AC, Gandhi PJ, Tataronis GR (2006). Statin-related adverse events: a

[23] Kashani A, Phillips CO, Foody JM, Wang Y, Mangalmurti S, Ko DT, Krumholz HM

[24] Grundy SM (2005). The issue of statin safety: where do we stand? Circulation 111:3016-

[25] Gholami K., Ziaie S., and Shalviri G (2008). Adverse drug reactions induced by

[26] Golomb BA, Kane T and Dimsdale JE (2004). Severe irritability associated with statin cholesterol-lowering agents. The Quarterly Journal of Medicine 97:229-235. [27] Golomb BA, Mcgraw JJ, Evans MA and Dimsdale JE (2007). Physician response to

[28] Sigonda N (2003). guidelines for monitoring and reporting adverse drug reactions

[29] Alsheikh-Ali AA, Ambrose MS, Kuvin JT, Karas RH (2005). The safety of rosuvastatin

[30] Hanston PD, and Horn JR (1998). Drug interactions with HMG CoA reductase

[31] EMEA (2002) Scientific conclusion and ground for withdrawal of the marketing

[32] Gray SL, Mahoney JE, Blough DK (1999). Adverse drug events in elderly patients

[33] Mabuchi H, Nohara A, Kobayashi J, Kawashiri MA, Inazu A (2007). Coenzyme Q10 Reduction with Statins: Another Pleiotropic Effect Current Drug Therapy 2: 39-51 [34] Kucukarslan SN, Peters M, Mlynarek M, Nafziger DA (2003). Pharmacists on rounding

[35] Corrao G, Zambon A, Bertù L, Botteri E, Leoni O, Contiero P (2004). Lipid lowering

[36] Agostini JV, Tinetti ME, Ling H, Mcavay G, Foody JM and Concato J (2007). Effects of

adults. The American Journal of Geriatric Cardiology in Society 55:420–425 [37] Jones P, Kafonek S, Laurora I, Hunninghake D (1998). Comparative dose efficacy study

(ADRs) made under section 5 (c) of the Tanzania food, drugs and cosmetics Act

as used in common clinical practice: a postmarketing analysis. Circulation 111:3051-

receiving home health services following hospital discharge. The Annals of

teams reduce preventable adverse drug events in hospital general medicine units.

drugs prescription and the risk of peripheral neuropathy: an exploratory casecontrol study using automated databases. Journal of Epidemiology Community

Statin use on muscle strength, Cognition, and Depressive Symptoms In older

of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (The Curves Study). The American Journal of

cardiovascular drugs in outpatients. Pharmacy Practice 6(1):51-55.

patient reports of adverse drug effects. Drug Safety 30(8): 669-675.

(2006). Risks associated with statin therapy: a systematic overview of randomized

meta-analysis. Clin Ther 28(1):26-35.

3019

2003

3057.

clinical trials. Circulation 114(25):2788-97.

inhibitors. Drug Interactions Newsletter 103-6

authorization presented, CPMP/811/02

Pharmacotherapy 33:1147-1153

Arch Intern Med 22;163(17):2014-8.

Health 58:1047–1051.

Cardiology 81:582–587


http://www.fda.gov/cder/drug/ infopage/rosuvastatin/default.htm


[6] AHFS (2007). HMG-CoA Reductase Inhibitors (Statins) – Safety Overview. Drug

[7] U.S food and drug administration: Rosuvastatin Calcium (marketed as Crestor)

[9] Ballantyne CM, Corsini A, Davidson MH, Holdaas H, Jacobson TA, Lieitersdorf E, Marz

[10] Clearfield MB, Amerena J, Bassand JP, Hernández García HR, Miller SS, Sosef FF,

[11] Golomb BA, Yang E, Denenberg J, Criqui M (2003). Statin-associated adverse events.

[12] Pasternak RC, Smith SCJ, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C (2002).

[14] Gaist D, Jeppesen U, Andersen M, García Rodríguez LA, Hallas J, Sindrup SH (2002).

[15] Committee on safety of medicines (2001). Cerivastatin (lipobay) withdrawn. Current

[16] Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH,

[17] Cheryl A (2007). HMG-CoA Reductase Inhibitors/Statins, PHARMD, UCSF School of

[18] Friedewald WT, Levy RI, Fredrickson DS (1972). Estimation of the concentration of low-

[19] Stone NJ and Blum CB (2008). Management of Lipids in Clinical Practice. Professional

[21] Zipes DP, Zvaifler NJ, Glassock RJ, Gilman S, Muñoz A, Gogolak V, Gordis L, Dedon

an independent analysis of risks and benefits. MedGenMed 8(2):73.

(WOSCOPS). The New England Journal of Medicine 333:1301-1307

Pharmacy, University of California at San Francisco.

[20] Brown WV (2008). Safety of statins. Curr Opin Lipidol 19(6):558-62

ultracentrifuge. Clinical Chemistry 18:499-502.

[13] Hamilton CI (2003). Statins and muscle damage. Australian Prescriber 26:74-75

http://www.fda.gov/cder/drug/ infopage/rosuvastatin/default.htm [8] Thompson PD, Clarkson P, Karas RH. (2003). Statin associated Myopathy. Journal of the

Information Patient information sheet. (2005) [Online]. [10th March 2008] available

W., Reckless, J PD, Stein EA (2003). Risk for myopathy with statin therapy in high-

Palmer MK and Bryzinski BS (2006). Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia – prospective study to evaluate the use of low doses of the statins atorvastatin and rosuvastatin (PULSAR). Licensee Biomed Central Ltd.

ACC/AHA/NHLBI Clinical advisory on the use and safety of statins. Journal of

Statins and risk of polyneuropathy: a case-control study. Neurology 14;

Packard CJ (1995). Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

density lipoprotein cholesterol in plasma without use of the preparative

PC, Guengerich FP, Wasserman SI, Witztum JL, Wogan GN (2006). Rosuvastatin:

Information Service, University of Utah.

American Medical Association 289:1681–1690

risk patients. Archive of Internal Medicine 163: 553-564.

the American College of Cardiology 106: 567–572

from World Wide Web:

Trial 7:35

58(9):1321-2.

Communications p80

Circulation 107; e7001-e7039, 95

Problem in Pharmacovigillance 27: 9


[38] Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F (1999). New insights

[39] Ravnskov U, Rosch PJ, Sutter MC, Houston MC (2006). Should we lower cholesterol as

Pharmacology and Therapeutic 84:413-428

much as possible? BMJ 332(7553):1330-1332.

into the pharmacodynamic and pharmacokinetic properties of statins.
